Supramolecular Nitric Oxide Depot for Hypoxic Tumor Vessel Normalization and Radiosensitization

Area of Science:

• Biomedical Engineering
• Cancer Research
• Radiotherapy

Background:

• Solid tumors often exhibit radioresistance due to hypoxia, which limits oxygen-dependent DNA damage fixation during radiotherapy.
• Nitric oxide (NO) is a known radiosensitizer, capable of directly fixing DNA damage and normalizing tumor vasculature to improve oxygen delivery.
• Precise control over NO dosage and duration is critical to avoid counterproductive effects, yet effective delivery methods are lacking.

Purpose of the Study:

• To develop and evaluate a novel nitric oxide (NO) depot system for controlled NO release.
• To investigate the efficacy of the NO depot in normalizing tumor vasculature and enhancing radiosensitization in hypoxic solid tumors.
• To assess the synergistic effects of dual-mode NO delivery (continuous low-dose and short-term high-dose) on reversing radioresistance.

Main Methods:

• Development of a NO depot designed for tunable release of nitric oxide over both quantity and duration.
• In vivo evaluation using B16-tumor-bearing mice models.
• Administration of NO via the depot, employing a dual-mode strategy: continuous low-dose release and immediate pre-irradiation high-dose burst.
• Assessment of tumor radiosensitization and vascular normalization effects.

Main Results:

• The NO depot successfully provided continuous low-dose NO and a short-term high-dose burst immediately before irradiation.
• This dual-mode NO delivery strategy synergistically reversed radioresistance in B16 tumors.
• The combined approach demonstrated superior efficacy in enhancing radiotherapy outcomes compared to single-dosage NO release methods.

Conclusions:

• The developed NO depot offers a promising strategy for controlled nitric oxide delivery in cancer radiotherapy.
• Dual-mode NO administration via the depot effectively normalizes tumor vasculature and enhances radiosensitization in hypoxic environments.
• This innovative approach holds potential for improving the efficacy of radiotherapy in treating radioresistant solid tumors.